Читать книгу Veterinary Surgical Oncology - Группа авторов - Страница 79

Greater than 50% of human patients will have unresectable esophageal neoplasia at the time of diagnosis (Burstow et al. 2009). The median survival time for these patients is between three and six months, and palliative treatments are often pursued due to the grave prognosis (Sabharwal et al. 2005; Wilkes et al. 2007). The palliation of dysphagia is essential to the patient’s quality of life, and esophageal stents are often placed in an attempt to achieve this goal (Sabharwal et al. 2005; Wilkes et al. 2007; Burstow et al. 2009). Esophageal stents have been shown to be an effective means of relieving malignant dysphagia secondary to malignant obstructions (Sabharwal et al. 2005; Wilkes et al. 2007; Burstow et al. 2009).

The use of esophageal stents in companion animals is controversial as the associated complications can be severe. Currently, only a single case report of an esophageal stent for relief of a malignant obstruction (squamous cell carcinoma) has been reported (Hansen et al. 2012). The placement of an esophageal stent, in that case, relieved the obstruction and improved clinical signs.